Ratings Medibank Private Limited

Equities

MPL

AU000000MPL3

Market Closed - Australian S.E. Other stock markets 02:10:51 2024-04-24 am EDT			5-day change	1st Jan Change
3.63 ^AUD	+0.28%		-1.63%	+1.97%

Mar. 06	Morgan Stanley Adjusts Medibank Private’s Price Target to AU$3.84 From AU$3.66, Keeps at Equalweight	MT
Feb. 23	Jarden Research Downgrades Medibank Private to Neutral From Overweight, Keeps Price Target at AU$3.75	MT

Summary

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
The company presents an interesting fundamental situation from a short-term investment perspective.
According to Refinitiv, the company's ESG score for its industry is good.

Strengths

Thanks to a sound financial situation, the firm has significant leeway for investment.
The company has attractive valuation levels with a low EV/sales ratio compared with its peers.
The company is one of the best yield companies with high dividend expectations.
Analysts remain confident with respect to the group's activity and, more often than not, have revised upwards their earnings per share estimates.
Over the past twelve months, analysts' opinions have been strongly revised upwards.
Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.

Weaknesses

The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
The company appears highly valued given the size of its balance sheet.
The overall consensus opinion of analysts has deteriorated sharply over the past four months.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Life & Health Insurance

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
MEDIBANK PRIVATE LIMITED	+1.97%	6.49B		C+
BUPA ARABIA FOR COOPERATIVE INSURANCE COMPANY	+16.21%	9.89B		B-
OSCAR HEALTH, INC.	+92.24%	4.04B		-
NIB HOLDINGS LIMITED	+2.30%	2.38B		B+
TRUPANION, INC.	-21.63%	1B		C
RELIGARE ENTERPRISES LIMITED	+5.63%	890M	-	D+
THE MEDITERRANEAN AND GULF COOPERATIVE INSURANCE AND REINSURANCE COMPANY	+90.28%	767M	-	C
AMANA COOPERATIVE INSURANCE COMPANY	+9.63%	164M	-	-
PT LIPPO GENERAL INSURANCE TBK	-7.65%	69.15M	-	-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes